ResMed (Germany) Performance
| RME Stock | EUR 219.60 0.80 0.36% |
The company holds a Beta of -0.11, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning ResMed are expected to decrease at a much lower rate. During the bear market, ResMed is likely to outperform the market. At this point, ResMed Inc has a negative expected return of -0.1%. Please make sure to check ResMed's daily balance of power, market facilitation index, and the relationship between the kurtosis and day median price , to decide if ResMed Inc performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days ResMed Inc has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest fragile performance, the Stock's basic indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders. ...more
| Begin Period Cash Flow | 295.3 M | |
| Total Cashflows From Investing Activities | -229.9 M |
ResMed |
ResMed Relative Risk vs. Return Landscape
If you would invest 23,577 in ResMed Inc on November 27, 2024 and sell it today you would lose (1,617) from holding ResMed Inc or give up 6.86% of portfolio value over 90 days. ResMed Inc is currently producing negative expected returns and takes up 1.7876% volatility of returns over 90 trading days. Put another way, 15% of traded stocks are less volatile than ResMed, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
ResMed Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ResMed's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ResMed Inc, and traders can use it to determine the average amount a ResMed's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0584
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RME |
Estimated Market Risk
| 1.79 actual daily | 15 85% of assets are more volatile |
Expected Return
| -0.1 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average ResMed is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ResMed by adding ResMed to a well-diversified portfolio.
ResMed Fundamentals Growth
ResMed Stock prices reflect investors' perceptions of the future prospects and financial health of ResMed, and ResMed fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ResMed Stock performance.
| Return On Equity | 0.24 | |||
| Return On Asset | 0.12 | |||
| Profit Margin | 0.22 % | |||
| Operating Margin | 0.28 % | |||
| Current Valuation | 31.17 B | |||
| Shares Outstanding | 146.91 M | |||
| Price To Earning | 41.49 X | |||
| Price To Book | 9.40 X | |||
| Price To Sales | 8.54 X | |||
| Revenue | 3.58 B | |||
| EBITDA | 1.19 B | |||
| Cash And Equivalents | 147.13 M | |||
| Cash Per Share | 1.03 X | |||
| Total Debt | 765.33 M | |||
| Debt To Equity | 61.30 % | |||
| Book Value Per Share | 25.45 X | |||
| Cash Flow From Operations | 351.15 M | |||
| Earnings Per Share | 5.17 X | |||
| Total Asset | 5.1 B | |||
About ResMed Performance
By analyzing ResMed's fundamental ratios, stakeholders can gain valuable insights into ResMed's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if ResMed has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if ResMed has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California. RESMED INC is traded on Frankfurt Stock Exchange in Germany.Things to note about ResMed Inc performance evaluation
Checking the ongoing alerts about ResMed for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ResMed Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ResMed Inc generated a negative expected return over the last 90 days | |
| The company has €765.33 Million in debt which may indicate that it relies heavily on debt financing | |
| About 67.0% of the company shares are owned by institutional investors |
- Analyzing ResMed's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ResMed's stock is overvalued or undervalued compared to its peers.
- Examining ResMed's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ResMed's management team can have a significant impact on its success or failure. Reviewing the track record and experience of ResMed's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ResMed's stock. These opinions can provide insight into ResMed's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for ResMed Stock analysis
When running ResMed's price analysis, check to measure ResMed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ResMed is operating at the current time. Most of ResMed's value examination focuses on studying past and present price action to predict the probability of ResMed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ResMed's price. Additionally, you may evaluate how the addition of ResMed to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |